Immunomodulatory agents for the treatment of relapsing multiple sclerosis: A systematic review Article Report uri icon

Overview

MeSH Major

  • Fructose
  • Pseudotumor Cerebri

abstract

  • Data show that the IMAs have similar effects on several physical and inflammatory measures. In addition, Avonex has demonstrated efficacy in slowing cognitive progression in relapsing MS. One disadvantage of interferon beta is the possibility of immunogenicity, which may occur more often with subcutaneous administration. The IMAs have similar safety and tolerability profiles.

publication date

  • October 28, 2002

Research

keywords

  • Report

Identity

Digital Object Identifier (DOI)

  • 10.1001/archinte.162.19.2161

PubMed ID

  • 12390057

Additional Document Info

start page

  • 2161

end page

  • 9

volume

  • 162

number

  • 19